Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies

BACKGROUND: Some chronic hepatitis C virus (HCV), genotype 1 infected patients treated with direct antiviral agents (DAAs) remain viremic at end of treatment (EOT+), yet go on to achieve sustained virological response 12 weeks after completion of therapy (SVR(12)). The incidence of EOT+/SVR in patie...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Therap Adv Gastroenterol
Hlavní autoři: Malespin, Miguel, Benyashvili, Tamara, Uprichard, Susan L., Perelson, Alan S., Dahari, Harel, Cotler, Scott J.
Médium: Artigo
Jazyk:Inglês
Vydáno: SAGE Publications 2016
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330612/
https://ncbi.nlm.nih.gov/pubmed/28286560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16672392
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky